Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 6, 2014, Pages 383-396

  Kornblau, Steven M ^a   Cohen, Aileen C ^b   Soper, David ^b   Huang, Ying Wen ^b   Cesano, Alessandra ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Nodality Inc   (United States)

Author keywords

age related bone marrow cell signaling; EPO; GCSF; MDS; SCNP; signaling

Indexed keywords

CD34 ANTIGEN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; SIGNAL PEPTIDE;

AGING; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE CELL NETWORK PROFILING; ADULT; AGE; AGED; ERYTHROID CELL; HEMATOPOIETIC STEM CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; REFRACTORY ANEMIA WITH EXCESS BLASTS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; BONE MARROW CELLS; ERYTHROID CELLS; ERYTHROPOIETIN; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84926192245     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21125     Document Type: Article

References (37)

1. Ma X,. Epidemiology of myelodysplastic syndromes. Am J Med 2012; 125: S2-S5.
2. Ershler WB, Sheng S, McKelvey J, Artz AS, Denduluri N, Tecson J, Taub DD, Brant LJ, Ferrucci L, Longo DL,. Serum erythropoietin and aging: A longitudinal analysis. J Am Geriatr Soc 2005; 53: 1360-1365.
3. Eisenstaedt R, Penninx BW, Woodman RC,. Anemia in the elderly: Current understanding and emerging concepts. Blood Rev 2006; 20: 213-226.
4. Musso CG, Musso CA, Joseph H, De Miguel R, Rendo P, Gonzalez E, Algranati L, dos Ramos Farias E,. Plasma erythropoietin levels in the oldest old. Int Urol Nephrol 2004; 36: 259-262.
5. Puglisi F, Deroma L, Russo S, Carteni G, Sporchia A, Ucci G, De Signoribus G, Del Prete S, Vecchione A, Pinotti G, et al. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients. Crit Rev Oncol Hematol 2009; 69: 175-182.
6. Chatta GS, Price TH, Allen RC, Dale DC,. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923-2929.
7. Lacayo N, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, et al. Development and validation of a single-cell network profiling (SCNP) assay-based classifier to predict response to induction therapy in pediatric patients with de novo acute myeloid leukemia (AML): A Report from the Children's Oncology Group. Br J Haematol 2013; 162: 250-262.
8. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A,. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res 2010; 16: 3721-3733.
9. Cesano A, Putta S, Rosen DB, Cohen AC, Gayko U, Mathi K, Woronicz J, Hawtin RE, Cripe L, Sun Z, et al. Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status. PLoS ONE 2013; 8: e56714.
10. Porwit A,. Role of flow cytometry in diagnostics of myelodysplastic syndromes-Beyond the WHO 2008 classification. Seminars Diagnostic Pathol 2011; 28: 273-282.
11. Vardiman J,. The classification of MDS: From FAB to WHO and beyond. Leukemia Res 2012; 36: 1453-1458.
12. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD,. Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118-129.
13. Mittelman M, Oster HS, Hoffman M, Neumann D,. The lower risk MDS patient at risk of rapid progression. Leuk Res 2010; 34: 1551-1555.
14. Aul C, Arning M, Runde V, Schneider W,. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res 1991; 15: 571-575.
15. Backx B, Broeders L, Hoefsloot LH, Wognum B, Lowenberg B,. Erythropoiesis in myelodysplastic syndrome: Expression of receptors for erythropoietin and kit ligand. Leukemia 1996; 10: 466-472.
16. Baines P, Bowen D, Jacobs A,. Clonal growth of haemopoietic progenitor cells from myelodysplastic marrow in response to recombinant haemopoietins. Leuk Res 1990; 14: 247-253.
17. Hoefsloot LH, van Amelsvoort MP, Broeders LC, van der Plas DC, van Lom K, Hoogerbrugge H, Touw IP, Lowenberg B,. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997; 89: 1690-1700.
18. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574-582.
19. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114: 2393-2400.
20. Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, Sanna A, Sassolini F, Valencia A, Bosi A, Santini V,. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Cancer Res 2012; 18: 3079-3089.
21. Frisan E, Pawlikowska P, Pierre-Eugene C, Viallon V, Gibault L, Park S, Mayeux P, Dreyfus F, Porteu F, Fontenay M,. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. Haematologica 2010; 95: 1964-1968.
22. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A,. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clinical Cancer Res 2010; 16: 3721-3733.
23. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, Nolan GP,. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217-228.
24. Shults KE, Miller DT, Davis BH, Flye L, Hobbs LA, Stelzer GT,. A standardized ZAP-70 assay-Lessons learned in the trenches. Cytometry Part B Clin Cytom 2006; 70: 276-283.
25. Purvis N, Stelzer G,. Multi-platform, multi-site instrumentation and reagent standardization. Cytometry 1998; 33: 156-165.
26. Wang L, Gaigalas AK, Marti G, Abbasi F, Hoffman RA,. Toward quantitative fluorescence measurements with multicolor flow cytometry. Cytometry A 2008; 73: 279-288.
27. Cesano A, Rosen DB, O'Meara P, Putta S, Gayko U, Spellmeyer DC, Cripe LD, Sun Z, Uno H, Litzow MR, et al. Functional pathway analysis in acute myeloid leukemia using Single Cell Network Profiling (SCNP) assay: Effect of specimen source (bone marrow or peripheral blood) on assay readouts. Cytometry Part B Clin Cytom 2012; 82: 158-172.
28. Covey TM, Cesano A,. Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications. Best Pract Res Clin Haematol 2010; 23: 319-331.
29. Cesano A, Gotlib JR, Lacayo NJ, Putta S, Lackey A, Gayko U, Kornblau SM,. Sample cryopreservation does not affect functional read outs in SCNP assays: Implications for biomarker development. Blood (ASH Annual Meeting Abstracts) 2010; 116: 4843.
30. Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer D, Marimpietri C, et al. Single cell network profiling (SCNP)-based classifier to predict response to induction therapy in elderly patients with acute myeloid leukemia (AML): Validation in two independent sample sets from ECOG and SWOG trials. Blood (ASH Annual Meeting Abstracts) 2012; 120.
31. Williams LH, Udupa KB, Lipshitz DA,. Evaluation of the effect of age on hematopoiesis in the C57BL/6 mouse. Exp Hematol 1986; 14: 827-832.
32. Berkahn L, Keating A,. Hematopoiesis in the elderly. Hematology 2004; 9: 159-163.
33. Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C,. Normal bone marrow signal-transduction profiles: A requisite for enhanced detection of signaling dysregulations in AML. Blood 2011; 117: e120-e130.
34. Woost PG, Solchaga LA, Meyerson HJ, Shankey TV, Goolsby CL, Jacobberger JW,. High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow. Blood 2011; 117: e131-e141.
35. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers HJ, Sekeres MA, Maciejewski JP, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
36. Damm F, Thol F, Kosmider O, Kade S, Loffeld P, Dreyfus F, Stamatoullas-Bastard A, Tanguy-Schmidt A, Beyne-Rauzy O, de Botton S, et al. SF3B1 mutations in myelodysplastic syndromes: Clinical associations and prognostic implications. Leukemia 2012; 26: 1137-1140.
37. Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B, Hellstrom-Lindberg E,. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101: 1080-1086.